Lv3
350 积分 2022-05-13 加入
Analysis of phase II and phase III clinical trial terminations from 2013 to 2023
4个月前
已完结
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
4个月前
已完结
Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis
5个月前
已完结
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
5个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
5个月前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
5个月前
已完结
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis
6个月前
已完结
Synthetic lethality in cancer drug discovery: challenges and opportunities
6个月前
已完结
Synthetic lethal strategies for the development of cancer therapeutics
6个月前
已完结
皖公网安备34019202002308
